Cat. #162321
Glioblastoma WHO IV spheroid cell line, NCH465
Cat. #: 162321
Organism: Human
Tissue: Brain
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christel Herold-Mende
Institute: Heidelberg University
Primary Citation: Bougnaud et al. 2016. Oncotarget. 7(22):31955-31971. PMID: 27049916.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Glioblastoma WHO IV spheroid cell line, NCH465
- Cancer: Brain
- Organism: Human
- Tissue: Brain
- Growth properties: Mixed - adherent and suspension
- Description: Glioblastoma WHO IV spheroid cell line, NCH465
- Biosafety level: 2
Handling
- Growth medium: DMEM-F12 supplemented with BIT100 supplement (Provitro), 2 mM L-glutamine, 30U/ml penicillin-steptomycin, 1U/ml heparin , 20ng/ml bFGF and 20ng/ml EGF
- Temperature: 37°C
- Atmosphere: 5% CO2
References
- Schuster et al. 2020. Nat Commun. 11(1):6366. PMID: 33311477.
- Biedermann et al. 2019. Cancers. 11(12). PMID: 31888244.
- Schulze et al. 2018. BMC Cancer. 18(1):524. PMID: 29724193.
- Hoja et al. 2016. Oncotarget. 7(39):62989-63002. PMID: 27556305.
- Bougnaud et al. 2016. Oncotarget. 7(22):31955-31971. PMID: 27049916.
- Campos et al. 2011. Am J Pathol. 178(5):1953–1964. PMID: 21514413.
